The US FDA's clearance of the trial marks the first global registrational Phase III trial for olverembatinib in patients with CP-CML to be conducted.
The agreement is effective from January 1, 2024 and commercialisation commenced on February 1, 2024
The 200 bedded hospital owned & operated by Alexis
Zydus’s revenue growth was led by India and EU formulations businesses in addition to that in the emerging markets.
The initiative, “Change the Odds: Uniting to Improve Cancer Outcomes” aims to enhance awareness of and access to cancer screening, clinical trials and support
Submission to be reviewed under FDA real-time oncology review and Project Orbis
About 75% of all primary liver cancers in adults are HCC and up to 30% of HCC patients are eligible for embolisation
This alliance brings together drug innovation capabilities of Glenmark and Ichnos to develop cutting-edge therapies for the treatment of hematological malignancies and solid tumors
Pivotal trial found the enfortumab vedotin plus pembrolizumab combination significantly extended overall and progression-free survival
Keynote -564 is the first Phase 3 trial to demonstrate superior overall survival (OS) with adjuvant therapy compared to placebo in patients with RCC
Subscribe To Our Newsletter & Stay Updated
